SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-13-166171
Filing Date
2013-04-23
Accepted
2013-04-23 09:00:37
Documents
6
Period of Report
2013-06-05
Effectiveness Date
2013-04-23

Document Format Files

Seq Description Document Type Size
1 DEFINITIVE PROXY STATEMENT d522854ddef14a.htm DEF 14A 611433
2 GRAPHIC g522854g07o65.jpg GRAPHIC 12466
3 GRAPHIC g522854g34q38.jpg GRAPHIC 8317
4 GRAPHIC g522854g80i40.jpg GRAPHIC 6878
5 GRAPHIC g522854pc_pg001.jpg GRAPHIC 110966
6 GRAPHIC g522854pc_pg002.jpg GRAPHIC 117910
  Complete submission text file 0001193125-13-166171.txt   966712
Mailing Address 3344 N. TORREY PINES CT. SUITE 200 LA JOLLA CA 92037
Business Address 3344 N. TORREY PINES CT. SUITE 200 LA JOLLA CA 92037 (858) 875-8600
Orexigen Therapeutics, Inc. (Filer) CIK: 0001382911 (see all company filings)

IRS No.: 651178822 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-33415 | Film No.: 13775282
SIC: 2834 Pharmaceutical Preparations